Rallybio Corp
RLYB
查看详细走势图
4.750USD
+0.099+2.12%
收盘 02/06, 16:00（美东）报价延迟15分钟
199.20M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.12%
5天
+639.76%
1月
+563.87%
6月
+829.55%
今年开始到现在
+592.32%
1年
+462.60%
查看详细走势图
TradingKey Rallybio Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Rallybio Corp当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名110/392位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价8.00。中期看，股价处于上升通道。近一个月，市场表现很强，技术面和基本面综合得分较高，很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Rallybio Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Rallybio Corp亮点
亮点风险
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
业绩增长期
公司处于发展阶段，最新年度总收入636.00K美元
估值低估
公司最新PE估值-15.13，处于3年历史低位
机构减仓
最新机构持股28.34M股，环比减少20.07%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.02M
活跃度降低
近期活跃度降低，过去20天平均换手率-0.43
分析师目标
根据
4
位分析师
持有
评级
1.000
目标均价
+73.85%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Rallybio Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Rallybio Corp简介
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
公司代码RLYB
公司Rallybio Corp
CEOUden (Stephen)
网址https://rallybio.com/
相关品种
